Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer

Abstract

AbstractObjectiveImmune checkpoint inhibitors (ICIs) or combined with chemotherapy exhibit substantial efficacy for the treatment of advanced non‐small cell lung cancer (NSCLC). However, reliable biomarkers that can monitor response to first‐line ICIs ± chemotherapy remain unclear.MethodsA total of 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment were retrospectively collected from 19 locally advanced or metastatic NSCLC patients. The circulating tumor DNA (ctDNA) burden by tumor‐informed assay was detected to monitor and predict the therapeutic response and survival of NSCLC patients treated with first‐line ICIs or plus chemotherapy.ResultsWe found that ctDNA was only positively detected in one patient by tumor‐agnostic assay with a mean variant allele fraction (VAF) of 6.40%, whereas it was positively detected in three patients by tumor‐informed assay with a mean VAF of 8.83%, 0.154%, and 0.176%, respectively. Tumor‐informed assays could sensitively detect ctDNA in 93.75% (15/16) of patients. Trends in the level of ctDNA from baseline to first evaluation was consistent with the radiographic changes. There was a greater decrease in ctDNA after treatment compared with baseline in patients with partial response compared to patients with stable disease/progressive disease. Patients with over a 50% reduction in ctDNA had a significant progression‐free survival and overall survival benefit.ConclusionThe tumor‐informed assay was favorable for ctDNA detection, and early dynamic changes in plasma ctDNA may be a valuable biomarker for monitoring the efficacy and predicting the outcome in advanced NSCLC patients treated with first‐line ICIs ± chemotherapy.